Selection of sample stories

Market access

 
Market access
 

Current HTA methods able to handle curative therapies – senior NICE adviser

Story

 - 11/09/2020 - 10:58

Pharma CEOs warn on reputational risks of fast-tracking Covid-19 vaccine

Story

 - 04/09/2020 - 11:57

Italy to provide Gilead's Veklury for Covid-19 on patient-by-patient basis due to 'extremely limited' availability

Story

 - 28/08/2020 - 12:05

Germany's patients and industry warn against 'cheapest drug' approach in biosimilar substitution

Story

 - 21/08/2020 - 15:31

EU and AstraZeneca reach first advance purchase agreement for a Covid-19 vaccine

Story

 - 14/08/2020 - 13:55

FDA to decide on Biogen/Eisai's aducanumab in March

Story

 - 07/08/2020 - 13:02

Gilead not relying on remdesivir for long-term growth - CEO O'Day

Story

 - 31/07/2020 - 14:40

Otsuka pulls EU filing for digital therapy Abilify MyCite after EMA raises concerns

Story

 - 24/07/2020 - 14:31

Covid-19 has changed the drug development landscape: the time for real-world data is here – experts

Story

 - 17/07/2020 - 12:57

Jardiance development 'one of biggest programmes ever' - Boehringer

Story

 - 10/07/2020 - 13:01

Gilead's remdesivir becomes first treatment approved in Europe for severe Covid-19

Story

 - 03/07/2020 - 14:18

Sanofi to axe up to 1,680 jobs in Europe by 2022

Story

 - 26/06/2020 - 15:23

European drugs' industry says mutual recognition agreement with UK is vital

Story

 - 19/06/2020 - 05:30

Germany wants to enforce EMA, ECDC and advance discussions on joint HTA in 'Europe of pioneers'

Story

 - 12/06/2020 - 15:27

Hydroxychloroquine shows no clinical benefit in Phase III in hospitalised patients with Covid-19 - study

Story

 - 05/06/2020 - 15:51

Plans to challenge IP of Covid-19 products are 'dangerous', say industry leaders

Story

 - 29/05/2020 - 14:06

Questions remain on responsibility for data collection as part of HTA reassessments in Canada

Story

 - 22/05/2020 - 12:34

Resolve to prioritise rare diseases treatments may weaken as prices hinder 'value for money' decision making, patient advocate warns

Story

 - 15/05/2020 - 13:02

European socialists add momentum to calls for greater EU health powers

Story

 - 07/05/2020 - 12:10

Industry cannot 'over promise and under deliver' on Covid-19, says MSD's chief patient officer

Story

 - 01/05/2020 - 14:25

WHO launches 'landmark' Covid-19 collaboration with world leaders but U.S. not included

Story

 - 24/04/2020 - 15:41

Industry joins regulators and U.S. NIH in developing coordinated research response to Covid-19

Story

 - 18/04/2020 - 06:00

EU winning points from drug industry for efforts to ease supplies

Story

 - 09/04/2020 - 12:03

European pharma sector struggling to stay in front in changing policy context

Story

 - 03/04/2020 - 14:26

Novartis' Zolgensma poised for European approval in latest round of CHMP decisions

Story

 - 27/03/2020 - 15:04

Canada first country to approve ViiV's once-monthly HIV combination Cabenuva

Story

 - 20/03/2020 - 14:48

EU drugmakers welcome new dialogue with Commission on corona crisis supplies

Story

 - 13/03/2020 - 16:46

AstraZeneca's Imfinzi combination fails Phase III bladder cancer trial

Story

 - 06/03/2020 - 08:20

Rare diseases must be priority in NICE review of methodologies, say senior industry figures

Story

 - 28/02/2020 - 14:08

Bankruptcies for antibiotic firms show need for new funding models, says UK envoy for AMR

Story

 - 21/02/2020 - 11:46

German Bundestag passes bill on HTA on key antibiotics, ATMPs and management of drug shortages

Story

 - 14/02/2020 - 14:48

NICE recognises 'pressure is on' for review of methodologies, says Boysen

Story

 - 07/02/2020 - 13:14

Roche braces for 2020 biosimilar impact of almost €4 billion

Story

 - 31/01/2020 - 16:26

Pfizer on U.S. launch plans for biosimilars of Roche's cancer drugs Avastin, Rituxan and Herceptin

Story

 - 24/01/2020 - 14:21

Single-arm, basket studies on Bayer's Vitrakvi insufficient for German HTA – IQWiG

Story

 - 17/01/2020 - 14:00

Almirall licenses potential inflammation treatment from genetic testing firm 23andMe

Story

 - 10/01/2020 - 13:26

Illumina abandons $1.2 billion deal to buy rival Pacific Biosciences

Story

 - 03/01/2020 - 08:05

Astellas buys Xyphos Biosciences in deal worth up to $665 million to boost immuno-oncology franchise

Story

 - 27/12/2019 - 07:38

Restricted reimbursement and 28% price cut on Novartis' migraine drug Aimovig in Germany, template for CRPG inhibitors

Story

 - 20/12/2019 - 13:15

'Smart' CAR-T cells could potentially work for solid tumours – Cellectis immunology VP

Story

 - 13/12/2019 - 14:15

device

Real news produced to inform your decisions on the health care markets

Your establishment is a subscriber but you have not initialized your access ?